Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
Joint Authors
Francescutti, Valerie
Mitsis, Demytra
Skitzki, Joseph J.
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-09-14
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Sarcoma tumors are rare and heterogeneous, yet they possess many characteristics that may facilitate immunotherapeutic responses.
Both active strategies including vaccines and passive strategies involving cellular adoptive immunotherapy have been applied clinically.
Results of these clinical trials indicate a distinct benefit for select patients.
The recent breakthrough of immunologic checkpoint inhibition is being rapidly introduced to a variety of tumor types including sarcoma.
It is anticipated that these emerging immunotherapies will exhibit clinical efficacy for a variety of sarcomas.
The increasing ability to tailor immunologic therapies to sarcoma patients will undoubtedly generate further enthusiasm and clinical research for this treatment modality.
American Psychological Association (APA)
Mitsis, Demytra& Francescutti, Valerie& Skitzki, Joseph J.. 2016. Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. Complexity،Vol. 2016, no. 2016, pp.1-6.
https://search.emarefa.net/detail/BIM-1115801
Modern Language Association (MLA)
Mitsis, Demytra…[et al.]. Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. Complexity No. 2016 (2016), pp.1-6.
https://search.emarefa.net/detail/BIM-1115801
American Medical Association (AMA)
Mitsis, Demytra& Francescutti, Valerie& Skitzki, Joseph J.. Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. Complexity. 2016. Vol. 2016, no. 2016, pp.1-6.
https://search.emarefa.net/detail/BIM-1115801
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1115801